title: Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease.
abstract: Six patients with fluctuating Parkinson's disease received single rising oral doses of the nonergot dopamine agonist CV 205-502 in an open experimental study. Doses of 0.5 mg produced antiparkinsonian effects of comparable intensity but longer duration than 200 mg of L-DOPA. CV 205-502, which combines structural features common to both ergolines and apomorphine, thus revealed interesting antiparkinsonian properties, but nausea and vomiting were dose-limiting side effects in all patients tested.
authors.affiliation: Department of Neurology, University Hospital Innsbruck, Austria.
authors.forename: W
authors.initials: W
authors.lastname: Poewe
authors.forename: G
authors.initials: G
authors.lastname: Luef
authors.forename: B
authors.initials: B
authors.lastname: Kleedorfer
authors.forename: M
authors.initials: M
authors.lastname: Emre
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000634:Aminoquinolines / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010302:Parkinson Disease, Secondary / Q000188:drug therapy*; D011954:Receptors, Dopamine / Q000187:drug effects*
chemical_list: D000634:Aminoquinolines; D011954:Receptors, Dopamine; C046650:quinagolide